Funder
Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–731.
2. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.
3. Uptravi SmPC. Uptravi® (selexipag) Summary of product characteristics (June 2022) 2022.
4. Uptravi® (selexipag) Full Prescribing Information. 2022. Uptravi® (selexipag) full prescribing information. Actelion Pharmaceuticals US, Inc.
5. McLaughlin V, Farber HW, Highland KB, et al. Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry). J Heart Lung Transplant. 2024;43(2):272–83.